JGC
APLS

J. Goldman & Co’s Apellis Pharmaceuticals APLS Stock Holding History

J. Goldman & Co’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-285,992
Closed -$7.18M – 661
2025
Q4 		$7.18M Buy
285,992
+2,839
+1% +$66.6K 0.19% 148
2025
Q3 		$6.41M Buy
283,153
+189,579
+203% +$4.42M 0.16% 171
2025
Q2 		$1.62M Buy
+93,574
New +$1.73M 0.04% 298
2023
Q3 		– Sell
-8,476
Closed -$372K – 363
2023
Q2 		$772K Sell
8,476
-82,549
-91% -$7.12M 0.03% 265
2023
Q1 		$6M Buy
+91,025
New +$5.25M 0.24% 123
2022
Q2 		– Sell
-40,377
Closed -$2.05M – 355
2022
Q1 		$2.05M Sell
40,377
-7,636
-16% -$337K 0.09% 202
2021
Q4 		$2.27M Buy
+48,013
New +$1.89M 0.13% 186

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

J. Goldman & Co's APLS Position: Q1 2026 in Review

J. Goldman & Co sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 285,992 shares — an estimated $7.18M sold.

J. Goldman & Co first reported a position in APLS in Q4 2021 and held it in 7 quarters. The position peaked at $7.18M in Q4 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • J. Goldman & Co reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • J. Goldman & Co sold 285,992 Apellis Pharmaceuticals shares in Q1 2026, an estimated $7.18M.
  • J. Goldman & Co first reported a position in Apellis Pharmaceuticals in Q4 2021 and held it in 7 quarters.
  • J. Goldman & Co's Apellis Pharmaceuticals position peaked at $7.18M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.